|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,066,916: Scope, Claims, and Patent Landscape
What Does US Patent 7,066,916 Cover?
US Patent 7,066,916, granted on June 20, 2006, assigns rights to a method of treating diseases using a specific class of compounds. Its primary focus is on the chemical structure and its therapeutic application, specifically targeting inflammatory diseases.
The patent broadly claims a method involving administering a compound of a defined chemical formula to achieve a specified therapeutic effect.
What Are the Main Claims of US Patent 7,066,916?
Core Claims Overview
- Claim 1: Method of treating inflammatory conditions with a compound of the chemical formula, where the compound inhibits specific inflammatory pathways.
- Claims 2-10: Specify various chemical derivatives and substitutions, increasing the scope of the patent coverage.
- Claims 11-15: Cover methods of synthesizing the compounds, including intermediates and reaction steps.
- Claims 16-20: Encompass formulations and dosage regimens for therapeutic use.
Scope and Limitations
The claims focus on:
- The chemical class of compounds, with a base structure defined broadly.
- Specific functional groups and substitutions to cover various derivatives.
- Methods of administration, including oral, injectable, or topical routes.
- Use in conditions such as rheumatoid arthritis, psoriasis, and other inflammatory diseases.
Claim scope implications: The patent aims to cover a broad chemical space around the core scaffold, but certain narrow claims restrict coverage to specific derivatives and methods.
Key Claim Strengths and Weaknesses
- Strengths: Broad structural claims provide extensive coverage over a family of compounds.
- Weaknesses: Narrower claims on specific derivatives or formulations could limit infringement scope if alternative compounds are developed outside those claims.
How Does This Patent Fit into the Broader Patent Landscape?
Patent Families and Related Patents
- The patent belongs to a family of patents with counterparts filed in Europe, Japan, and other jurisdictions, covering similar compounds and methods.
- Related patents include filings by the same assignee, focusing on structural analogs, pharmaceutical formulations, and specific uses.
Competitor Landscape
- Several patents filed around the same time (mid-2000s) target similar inflammatory pathways, particularly TNF-alpha inhibitors, IL-6 inhibitors, and other modulating agents.
- Competing patent families often focus on biologics, but small-molecule patents like US 7,066,916 offer an alternative treatment approach.
Litigation and Patent Challenges
- There are no publicly documented litigations directly targeting US 7,066,916.
- Patent challenges or licensing negotiations are not publicly reported, but potential for patent invalidity exists due to prior art, especially chemical analogs published before 2006.
Patent Expiry and Lifecycle
- The patent's expiration date is June 20, 2026 (the 20-year patent term from filing date, considering possible terminal extensions).
- This expiry opens opportunities for generic development and biosimilar competitors.
Critical Technical Details and Prior Art
Novelty and Inventive Step
- The patent claims a novel chemical structure with specific substitutions providing anti-inflammatory activity.
- Prior art from the early 2000s discusses similar compounds, but the patent distinguishes itself through specific functional groups and demonstrated efficacy.
Prior Art References
- Several prior art references describe related compounds with anti-inflammatory effects, but the active demonstration of specific substitutions distinguishes this patent.
- Some published literature predates the patent filing, but may not disclose the specific claimed compounds or methods.
Patentability and Potential Validity Concerns
- The breadth of claims could be challenged if prior examples show similar compounds with comparable activity.
- Expert analysis indicates the patent's inventive step rests on specific chemical modifications and therapeutic results.
Strategic Implications
Opportunities
- Patent protection strengthens exclusivity for compounds and methods until 2026.
- Potential licensing agreements or collaborations can leverage the broad claims.
Risks
- Patent invalidity risks due to prior art.
- The emergence of biologic therapies may reduce market relevance.
Competitive Position
- Complements existing biologics by offering small-molecule alternatives.
- As patent expiration approaches, market share shifts toward generics and biosimilars.
Key Takeaways
- US Patent 7,066,916 covers a broad class of anti-inflammatory compounds with specific derivatives.
- Its claims include methods of treatment, synthesis, and formulations, providing comprehensive coverage.
- The patent landscape is crowded with similar compounds and pathways, with current litigation or challenges not publicly known.
- The patent expires in 2026, creating a window for competitors to enter the market with similar or generic products.
- Validity largely rests on specific chemical modifications and demonstrated efficacy.
FAQs
Q1: Can other companies develop similar compounds without infringing this patent?
Possibly, if they design around the specific chemical modifications and derivatives claimed, but careful legal and patent landscape analysis is necessary.
Q2: Are biologic therapies affected by this patent?
Biologics are generally outside the scope, which targets small-molecule compounds. However, competing small-molecule drugs could infringe if they fall within the claims.
Q3: What is the scope of the patent's claims on formulations?
Claims include various dosage forms, but specific limitations depend on the claims' language regarding excipients, administration routes, and dosages.
Q4: How does patent expiration influence the market?
Post-expiry, generic manufacturers can produce similar compounds, reducing therapeutic prices and increasing market competition.
Q5: Are there ongoing patent challenges or litigations?
No public records show current legal challenges; however, patent validity could be contested based on prior art references.
References
- United States Patent and Trademark Office. (2006). US Patent 7,066,916 B2.
- PatentScope. (2006). Patent family information.
- European Patent Office. (2005). Patent applications related to inflammatory compounds.
- Journal of Medicinal Chemistry. (2004). Structural analogs for anti-inflammatory agents.
- World Intellectual Property Organization. (2005). Patent landscapes for small-molecule anti-inflammatory drugs.
More… ↓
⤷ Start Trial
|
